期刊
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
卷 -, 期 -, 页码 -出版社
ENDOCRINE SOC
DOI: 10.1210/clinem/dgad134
关键词
congenital adrenal hyperplasia; 11-oxygenated androgens; 17-hydroxyprogesterone
The most common form of congenital adrenal hyperplasia is 21-hydroxylase deficiency (21OHD), occurring in 1:16 000 newborns worldwide. Lifelong treatment aims to replace deficiencies and suppress androgen production, but balancing between androgen excess and chronic high glucocorticoid exposure is challenging. Clinical assessment and biochemical parameters guide therapy, and understanding adrenal biomarker values is important. The pathophysiologic and pharmacologic principles are utilized to manage complications and consequences of 21OHD.
The most common form of congenital adrenal hyperplasia is 21-hydroxylase deficiency (21OHD), which in the classic (severe) form occurs in roughly 1:16 000 newborns worldwide. Lifelong treatment consists of replacing cortisol and aldosterone deficiencies, and supraphysiological dosing schedules are typically employed to simultaneously attenuate production of adrenal-derived androgens. Glucocorticoid titration in 21OHD is challenging as it must balance the consequences of androgen excess vs those from chronic high glucocorticoid exposure, which are further complicated by interindividual variability in cortisol kinetics and glucocorticoid sensitivity. Clinical assessment and biochemical parameters are both used to guide therapy, but the specific purpose and goals of each biomarker vary with age and clinical context. Here we review the approach to medication titration for children and adults with classic 21OHD, with an emphasis on how to interpret adrenal biomarker values in guiding this process. In parallel, we illustrate how an understanding of the pathophysiologic and pharmacologic principles can be used to avoid and to correct complications of this disease and consequences of its management using existing treatment options.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据